FOLR1 and ovarian cancer: The results from the FORWARD II trial (NCT02606305) indicated that eighteen women with relapsed FRα‐positive and platinum‐sensitive ovarian cancer were treated with carboplatin in combination with mirvetuximab soravtansine.263